Clinical Trials: Clinical Trials in China

Clinical Research Professional Training Standards in China

Posted on digi By digi

Sponsors and CROs should:
✔️ Require documented GCP training for all trial staff
✔️ Provide refresher courses every three years or with major protocol changes
✔️ Partner with accredited providers for standardized training
✔️ Audit site training records during feasibility and initiation
✔️ Invest in role-specific training (investigator vs CRA vs CRC)
These measures ensure compliance and reduce inspection risks.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Real-World Evidence Studies in Chinese Regulatory Submissions

Posted on digi By digi

Sponsors should:
✔️ Define regulatory objectives for RWE early in development
✔️ Partner with hospitals and registries to ensure data quality
✔️ Implement standardized data cleaning and validation procedures
✔️ Use advanced analytics, including AI, to reduce bias
✔️ Engage regulators early to align expectations on RWE use
✔️ Leverage CROs with expertise in RWE operations in China
These practices enhance the credibility and acceptance of RWE in submissions.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

GCP Inspection Trends in China (Recent Findings)

Posted on digi By digi

Sponsors should:
✔️ Conduct mock inspections and internal audits
✔️ Ensure complete and accurate TMF documentation
✔️ Maintain validated electronic systems with audit trails
✔️ Provide regular GCP training for investigators and CRCs
✔️ Strengthen CRO oversight through QA audits
✔️ Prepare inspection readiness plans at both sponsor and site levels
Proactive measures reduce inspection risks and build credibility with regulators.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Post-COVID Clinical Research Resilience in China

Posted on digi By digi

Sponsors should:
✔️ Incorporate decentralized elements into trial protocols
✔️ Validate electronic systems for monitoring and eConsent
✔️ Diversify supply chains and invest in local manufacturing
✔️ Maintain flexible SOPs for protocol deviations
✔️ Strengthen CRO partnerships for crisis management
✔️ Engage regulators and ethics committees early in disruption scenarios
These practices create resilient clinical trial frameworks that can withstand future challenges.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Oncology Biomarker-Driven Trials in China

Posted on digi By digi

Sponsors should:
✔️ Engage with NMPA and HGRAC early for biomarker and genomic testing approvals
✔️ Partner with Tier-1 hospitals and genomic laboratories for assay validation
✔️ Use standardized, globally recognized biomarker assays
✔️ Train site staff in biomarker testing and data management
✔️ Ensure data security and compliance with localization laws
✔️ Collaborate with CROs specializing in biomarker-driven trials
These practices reduce regulatory risks and improve trial efficiency.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Multi-Regional Clinical Trials Including China: Best Practices

Posted on digi By digi

Sponsors should:
✔️ Engage NMPA early for protocol and patient enrollment guidance
✔️ Select sites based on MRCT readiness and ethics capacity
✔️ Implement bilingual systems for CRFs and TMFs
✔️ Train investigators in ICH E17 MRCT principles
✔️ Partner with CROs for operational support and inspections
✔️ Monitor recruitment diversity to meet global regulatory expectations
These practices ensure successful integration of Chinese data into global MRCTs.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

China’s Role in ICH E17 MRCT Guidelines Implementation

Posted on digi By digi

Sponsors should:
✔️ Engage with the NMPA early for MRCT protocol review
✔️ Allocate sufficient Chinese patient enrollment for subgroup analysis
✔️ Harmonize CRFs and TMFs with global CDISC standards
✔️ Prepare Chinese sites for multinational inspections
✔️ Partner with CROs with strong China expertise
✔️ Incorporate bilingual training for investigators and site staff
These practices ensure successful implementation of ICH E17 in China.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Import & Export Licensing of Investigational Products in China

Posted on digi By digi

Sponsors should:
✔️ Begin licensing applications well in advance of trial initiation
✔️ Engage CROs and logistics vendors with China-specific expertise
✔️ Verify accuracy of all documentation before shipment
✔️ Train site staff on customs clearance and chain-of-custody requirements
✔️ Build contingency timelines for potential delays
These preventive measures ensure timely trial initiation and compliance with regulatory expectations.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Local Manufacturing Requirements for IMPs in Chinese Clinical Trials

Posted on digi By digi

Sponsors should:
– Select NMPA-accredited GMP facilities early in planning.
– Validate manufacturing and packaging processes before trial initiation.
– Ensure all labeling complies with Mandarin-language requirements.
– Audit local manufacturers and CROs regularly for compliance.
– Maintain complete batch records and stability data.
– Train staff in GMP, GSP, and clinical supply chain requirements.
These measures safeguard compliance and ensure uninterrupted IMP supply.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Timelines for IND vs NDA Clinical Development in China

Posted on digi By digi

Sponsors should:
– Plan IND submissions well in advance with complete preclinical data.
– Anticipate NMPA queries and prepare responses before submission.
– Leverage accelerated pathways for breakthrough or rare disease therapies.
– Prepare GMP and GCP inspections early during NDA preparation.
– Align with CROs for dossier preparation and submission in eCTD format.
These best practices ensure smoother navigation of IND and NDA timelines.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials